By Carlo Martuscelli


Roche Holding AG (ROG.EB) raised its guidance on Wednesday after reporting that sales rose 9.5% in the period from January to September.

Sales in the nine months totaled 46.07 billion Swiss francs ($46.16 billion), up from CHF42.08 billion a year earlier. U.S. sales were particularly strong, rising 17% to CHF20.04 billion.

The Swiss drugmaker said it now expects high-single-digit sales growth at constant exchange rates in 2019, with core earnings per share increasing in line with sales.

Previously, the company had guided for mid-to-high-single-digit growth at constant exchange rates.

Roche said a strong performance from multiple sclerosis drug Ocrevus, as well as hemophilia medicine Hemlibra and cancer medicines Tecentriq, Perjeta and Avastin helped to offset declining sales of Herceptin and MabThera/Rituxan, which were hit by competition from closely-resembling drugs.


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

October 16, 2019 01:33 ET (05:33 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Roche (QX) Charts.
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Roche (QX) Charts.